It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...
Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...
Regeneron’s cut from the Dupixent sales boom was $2.11 billion in the quarter, which topped analysts’ consensus by $358 ...
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a ...
The FDA has rebuked Viatris for a direct-to-consumer (DTC) video that allegedly misled viewers about a cystic fibrosis ...
Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to ...
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of ...
Roche’s cancer treatment Avastin (bevacizumab) has long been employed as an off-label option for wet age-related macular ...
Amgen, LeBron James and world’s top-subscribed YouTuber MrBeast may sound like a Mad Lib of unrelated influences, but the ...
The three-year initiative is designed to generate 1.9 billion pound sterling ($2.5 billion) in annual cost savings by 2029, against 2.4 billion pound sterling in total one-time costs. The cost ...
New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing the ...
Despite Robert F. Kennedy Jr. ultimately agreeing to divest referral fees tied to litigation around Merck & Co.’s HPV vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results